Page 139 - CW E-Magazine (17-6-2025)

CSIR- National Chemical Laboratory

Novel Process for the Production of IMEGLIMIN

Process Highlights

 Reusable novel Heterogeneous Catalyst
 100% Key Starting Material conversion IMEGLIMIN
 Highly selective (97%) process
 High Racemic yields (up to 85%) Metformin Substitute:
 Less effluent discharge Type-2 Diabetes
 Reduced reaction time Treatment
 Reusable solvent

Technology Available For Licensing/ Co-development

Background MARKET

India's Type-2 diabetes cases may reach o TWYMEEG® net sales in Japan has reached
134 million by 2045 JPY 5 billion (USD 33 million) in 2024
Prolonged use of Metformin can cause o India has approved Imeglimin in January
gastro intolerance & vit B-12 deficiency 2023
Imeglimin (TWYMEEG®), a novel & safer
Technology Offeringology Offering
alternative, was launched in Japan. Techn
Our technology offering improves its
synthesis & economics by addressing  Reusable Heterogeneous Catalyst
existing issues of solubility limitations,
longer reaction time, more down-  Batch Size: 10 kg
streaming steps & water footprints etc.
 Reduced water footprint

Value Proposition  Racemic Yield 85%
 Inexpensive heterogeneous catalyst  Efficient downstream protocol

 Scalable & Cost-effective Process
 Racemic Yield of up to 85%  Reusable Solvent
 Significant reduction in wastewater
Generation Application:
 Improved solubility limitations Treatement of Type-2 Diabetes
 Less Downstreaming steps
IP: PCT/IN2025/050724

Contact: Dr. Mangesh Vetal Address: CSIR-National Chemical Laboratory,
Email: md.vetal@ncl.res.in Dr. Homi Bhabha Road, Pune - 411 008, India.
Phone No: +91-20-2590-2138 Website: www.ncl-india.org

Chemical Weekly June 17, 2025 139

Contents Index to Advertisers Index to Products Advertised